Literature DB >> 9111009

Mapping of a cytoplasmic domain of the human growth hormone receptor that regulates rates of inactivation of Jak2 and Stat proteins.

R H Hackett1, Y D Wang, S Sweitzer, G Feldman, W I Wood, A C Larner.   

Abstract

It has been previously demonstrated that growth hormone (GH)-stimulated tyrosine phosphorylation of Jak2 and Stat5a and Stat5b occurs in FDP-C1 cells expressing either the entire GH receptor or truncations of the cytoplasmic domain expressing only the membrane-proximal 80 amino acids. However, other receptor domains that might modulate rates of GH activation and inactivation of this cascade have not been examined. Here we have defined a region in the human GH receptor between amino acids 520 and 540 in the cytoplasmic domain that is required for attenuation of GH-activated Jak/Stat signaling. Immunoprecipitations with antibodies to Jak2 indicate that the protein tyrosine phosphatase SHP-1 is associated with this kinase in cells exposed to GH. To address the possibility that SHP-1 could function as a negative regulator of GH signaling, liver extracts from motheaten mice deficient in SHP-1 or unaffected littermates were analyzed for activation of Stats and Jak2. Extracts from motheaten mice displayed prolonged activation of the Stat proteins as measured by their ability to interact with DNA and prolonged tyrosine phosphorylation of Jak2. These results delineate a novel domain in the GH receptor that regulates the inactivation of the Jak/Stat pathway and appears to be modulated by SHP-1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111009     DOI: 10.1074/jbc.272.17.11128

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.

Authors:  C Bousquet; C Susini; S Melmed
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Growth hormone-induced JAK2 signaling and GH receptor down-regulation: role of GH receptor intracellular domain tyrosine residues.

Authors:  Luqin Deng; Jing Jiang; Stuart J Frank
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

3.  Pathogenic signaling in multiple myeloma.

Authors:  Arnold Bolomsky; Ryan M Young
Journal:  Semin Oncol       Date:  2022-01-20       Impact factor: 5.385

Review 4.  Growth hormone receptor modulators.

Authors:  Vita Birzniece; Akira Sata; Ken K Y Ho
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

5.  Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.

Authors:  K C Leung; N Doyle; M Ballesteros; K Sjogren; C K W Watts; T H Low; G M Leong; R J M Ross; K K Y Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

6.  Protein tyrosine phosphatase 1B attenuates growth hormone-mediated JAK2-STAT signaling.

Authors:  Feng Gu; Nadia Dubé; Jin Wook Kim; Alan Cheng; Maria de Jesus Ibarra-Sanchez; Michel L Tremblay; Yves R Boisclair
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

7.  IGF-1R modulation of acute GH-induced STAT5 signaling: role of protein tyrosine phosphatase activity.

Authors:  Yujun Gan; Yue Zhang; Ashiya Buckels; Andrew J Paterson; Jing Jiang; Thomas L Clemens; Zhong-Yin Zhang; Keyong Du; Yingzi Chang; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2013-09-12

Review 8.  Recent advances in growth hormone signaling.

Authors:  Nathan J Lanning; Christin Carter-Su
Journal:  Rev Endocr Metab Disord       Date:  2006-12       Impact factor: 9.306

Review 9.  Classical and novel GH receptor signaling pathways.

Authors:  Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2020-08-22       Impact factor: 4.102

Review 10.  Post-Receptor Inhibitors of the GHR-JAK2-STAT Pathway in the Growth Hormone Signal Transduction.

Authors:  Maciej Wójcik; Agata Krawczyńska; Hanna Antushevich; Andrzej Przemysław Herman
Journal:  Int J Mol Sci       Date:  2018-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.